Carmen D. Zorrilla to RNA, Viral
This is a "connection" page, showing publications Carmen D. Zorrilla has written about RNA, Viral.
Connection Strength
0.368
-
Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galv?o LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth. 2019 Aug 07; 19(1):282.
Score: 0.152
-
Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jim?nez E, McSherry G, Mofenson L. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother. 2007 Jun; 51(6):2208-10.
Score: 0.065
-
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1429-41.
Score: 0.036
-
F?tkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 Oct 02; 359(14):1442-55.
Score: 0.036
-
Navas-Nacher EL, Read JS, Leighty RM, Tuomala RE, Zorrilla CD, Landesman S, Rosenblatt H, Hershow RC. Mode of delivery and postpartum HIV-1 disease progression: the Women and Infants Transmission Study. AIDS. 2006 Feb 14; 20(3):429-36.
Score: 0.015
-
Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC. Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr. 2004 Nov 01; 37(3):1423-30.
Score: 0.014
-
Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jim?nez E, Mofenson L. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004 Feb; 48(2):430-6.
Score: 0.013
-
Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla CD, Hammill H, Adeniyi-Jones SK, Thompson B. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol. 2003 Aug; 189(2):552-9.
Score: 0.013
-
Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, Huang S, Sperling RS, Cunningham B, Gandia J, Maupin R, Zorrilla CD, Jones T, O'Sullivan MJ. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr. 2003 Feb 01; 32(2):170-81.
Score: 0.012
-
Tuomala RE, O'Driscoll PT, Bremer JW, Jennings C, Xu C, Read JS, Matzen E, Landay A, Zorrilla C, Blattner W, Charurat M, Anderson DJ. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003 Feb 01; 187(3):375-84.
Score: 0.012